Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Related Articles by Review for PubMed (Select 21136019)

1.

Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.

Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK.

Thromb Haemost. 2011 Mar;105(3):444-53. doi: 10.1160/TH10-09-0601. Epub 2010 Dec 6.

PMID:
21136019
2.

A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.

Turun S, Banghua L, Yuan Y, Zhenhui L, Ying N, Jin C.

Thromb Res. 2011 Jun;127(6):525-34. doi: 10.1016/j.thromres.2011.01.016. Epub 2011 Mar 12. Review.

PMID:
21397931
3.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

4.

Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.

Duggan ST.

Am J Cardiovasc Drugs. 2012 Feb 1;12(1):57-72. doi: 10.2165/11208470-000000000-00000. Review.

PMID:
22272729
5.

Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.

Kwong LM.

Am J Manag Care. 2011 Feb;17(1 Suppl):S22-6. Review.

7.
8.

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.

Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H.

Thromb Haemost. 2010 Oct;104(4):760-70. doi: 10.1160/TH10-01-0071. Epub 2010 Aug 30. Review.

PMID:
20806107
9.

Rivaroxaban: an oral factor Xa inhibitor.

Thomas TF, Ganetsky V, Spinler SA.

Clin Ther. 2013 Jan;35(1):4-27. doi: 10.1016/j.clinthera.2012.12.005. Review.

PMID:
23328267
10.

Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Duggan ST, Scott LJ, Plosker GL.

Drugs. 2009;69(13):1829-51. doi: 10.2165/11200890-000000000-00000. Review.

PMID:
19719335
11.

The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.

Cohen AT, Dobromirski M.

Thromb Haemost. 2012 Jun;107(6):1035-43. doi: 10.1160/TH11-12-0859. Epub 2012 Feb 28. Review.

PMID:
22371186
12.

[Rivaroxaban (Xarelto): efficacy and safety].

Rosencher N, Arnaout L, Chabbouh T, Bellamy L.

Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S22-7. doi: 10.1016/S0750-7658(08)75143-8. Review. French.

PMID:
19185784
13.

Dabigatran etexilate: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.

Burness CB, McKeage K.

Drugs. 2012 May 7;72(7):963-86. doi: 10.2165/11209080-000000000-00000. Review.

PMID:
22564134
14.

Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons.

Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E.

BMJ. 2012 Jun 14;344:e3675. doi: 10.1136/bmj.e3675. Review.

15.

A critical appraisal of bleeding events reported in venous thromboembolism prevention trials of patients undergoing hip and knee arthroplasty.

Dahl OE, Quinlan DJ, Bergqvist D, Eikelboom JW.

J Thromb Haemost. 2010 Sep;8(9):1966-75. doi: 10.1111/j.1538-7836.2010.03965.x. Review.

PMID:
20586919
16.

Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.

Eriksson BI, Friedman RJ.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:25S-31S. doi: 10.1177/1076029609340668. Epub 2009 Jul 31. Review.

PMID:
19648146
17.

Pharmacodynamic and pharmacokinetic basics of rivaroxaban.

Kreutz R.

Fundam Clin Pharmacol. 2012 Feb;26(1):27-32. doi: 10.1111/j.1472-8206.2011.00981.x. Epub 2011 Aug 16. Review.

PMID:
21848931
18.

Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.

Holmes M, Carroll C, Papaioannou D.

Health Technol Assess. 2009 Sep;13 Suppl 2:55-62. doi: 10.3310/hta13suppl2/08. Review.

19.

Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.

Turpie AG.

Surg Technol Int. 2004;13:261-7. Review.

PMID:
15744699
20.

Apixaban: a review of its use in the prevention of venous thromboembolism after knee or hip replacement surgery.

Deeks ED.

Drugs. 2012 Jun 18;72(9):1271-91. doi: 10.2165/11209020-000000000-00000. Review.

PMID:
22686618
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk